Scilex Holding Company

Scilex Holding Company announced that its Dream Bowl I Meme Coin tokens commenced trading on the Biconomy Exchange on July 6, 2026. The company believes this listing may provide liquidity and broad distribution for the tokens previously distributed to stockholders and certain other eligible equityholders. Biconomy serves over 10 million users across more than 180 countries, ranks among the top 40 global exchanges by trading volume, and has an average daily volume of approximately $2.0 billion. Scilex currently holds approximately 180 million Dream Bowl Tokens following the distribution to participating holders as of the record date of April 30, 2026.

Scilex Holding jumped 7% in premarket trading after announcing a binding term sheet for a proposed $100 million strategic investment from Kazakhstan-based private investment group iHolding Group LLP. Vera Therapeutics gained 6% ahead of its July 7 Prescription Drug User Fee Act decision for atacicept, its investigational treatment for IgA nephropathy. Solaris Energy Infrastructure rose 3.9% after Wolfe Research initiated coverage with an Outperform rating and a $120 price target, and the company also announced the acquisition of power generation services provider Global Energy Services Alliance for approximately $55 million in cash and stock. Strategy climbed 3.4% as investors continued to digest the company's newly adopted Digital Credit Capital Framework, which authorizes the selective monetization of up to $1.25 billion of its Bitcoin holdings to bolster liquidity, fund preferred dividends and support share repurchases.

Scilex Holding Company shares climbed 7% on Monday after the company announced it had signed a binding term sheet for a proposed $100 million strategic investment from Kazakhstan-based private investment firm iHolding Group LLP. Under the proposed agreement, iHolding would acquire approximately 6.7 million newly issued Scilex common shares at $15.00 per share. The investment would provide additional capital to support Scilex's long-term expansion strategy across healthcare and medical technology, including product development, commercialization activities, acquisitions, and general working capital requirements. The transaction remains subject to customary closing conditions, including due diligence, negotiation and execution of definitive agreements, board approvals, shareholder approval, and any necessary regulatory clearances. Scilex specializes in non-opioid therapies for acute and chronic pain, and the proposed financing would represent one of the largest healthcare investments from Kazakhstan into a U.S.-listed biopharmaceutical company in recent years.